Candidates: Messenger RNA (mRNA) vaccines

Category: RNAVAX

Types: Next generation mRNA vaccines

Status: GlaxoSmithKline (GSK) and CureVac said February 3 they will partner exclusively to jointly develop a number of next generation mRNA vaccines for COVID-19, including multi-valent and monovalent approaches, with the potential of addressing multiple emerging variants in one vaccine. GSK and CureVac said they aim to introduce their vaccine in 2022, subject to regulatory approval.

GSK will be the marketing authorization holder for the next generation vaccine, except in Switzerland, and will have exclusive rights to develop, manufacture, and commercialize the next generation COVID-19 vaccine in all countries with the exception of Germany, Austria and Switzerland. GSK will make an upfront payment of €75 million ($90 million) and another €75 million tied to achieving milestones.

COVID-19: 300 Candidates and Counting

To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types: